These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
51. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490 [TBL] [Abstract][Full Text] [Related]
52. Successful epoprostenol withdrawal in pulmonary arterial hypertension: case report and literature review. Demerouti EA; Manginas AN; Athanassopoulos GD; Karatasakis GT; Leontiadis ED; Pavlides GS Respir Care; 2013 Feb; 58(2):e1-5. PubMed ID: 22710078 [TBL] [Abstract][Full Text] [Related]
53. Endothelin antagonism in pulmonary arterial hypertension. Lee SH; Channick RN Semin Respir Crit Care Med; 2005 Aug; 26(4):402-8. PubMed ID: 16121317 [TBL] [Abstract][Full Text] [Related]
54. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. Beghetti M; Galiè N J Am Coll Cardiol; 2009 Mar; 53(9):733-40. PubMed ID: 19245962 [TBL] [Abstract][Full Text] [Related]
55. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974 [TBL] [Abstract][Full Text] [Related]
56. Treprostinil to reverse pulmonary hypertension associated with idiopathic pulmonary fibrosis as a bridge to single-lung transplantation. Saggar R; Shapiro SS; Ross DJ; Fishbein MC; Zisman DA; Lynch JP; Weigt SS; Ardehali A; Belperio JA; Saggar R J Heart Lung Transplant; 2009 Sep; 28(9):964-7. PubMed ID: 19716051 [TBL] [Abstract][Full Text] [Related]
57. Successful switch from long-term intravenous iloprost to non-invasive combination therapy in idiopathic pulmonary arterial hypertension. Halank M; Kolditz M; Opitz C; Hoeffken G; Ewert R Wien Klin Wochenschr; 2006 Feb; 118(1-2):54-9. PubMed ID: 16489527 [TBL] [Abstract][Full Text] [Related]
58. Recent advances in the treatment of pediatric pulmonary artery hypertension. Barst RJ Pediatr Clin North Am; 1999 Apr; 46(2):331-45. PubMed ID: 10218078 [TBL] [Abstract][Full Text] [Related]
59. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. Lunze K; Gilbert N; Mebus S; Miera O; Fehske W; Uhlemann F; Mühler EG; Ewert P; Lange PE; Berger F; Schulze-Neick I Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008 [TBL] [Abstract][Full Text] [Related]
60. Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension. Leibovitch L; Matok I; Paret G Drugs; 2007; 67(1):57-73. PubMed ID: 17209664 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]